① Jexin Medical completed tens of millions of yuan in angel + round financing, with the funds used for factory construction, marketing, and research and development. Its interatrial puncture system and balloon mapping catheter have obtained registration certificates from the National Medical Products Administration and are on the market. ② Aikemai Medical Devices completed over 100 million yuan in Pre-B round financing; Newmai Medical’s IPO on the Sci-Tech Innovation Board was accepted; Huaitai Medical, Bairen Medical, and Sainuo Medical are advancing commercialization or achieving revenue growth in related fields.
In September 2026, tens of millions of yuan in angel and Series A financing was completed. The funds were used for factory construction, market promotion, and research and development.
In September 2026, Shanghai Jexin Medical Technology Co., Ltd. completed a Series A+ financing of tens of millions of yuan. Chengshu Investment led the investment, with Sanjiang Capital and Qianrong Holding participating as backers, and old shareholder Daoyuan Capital continuing to contribute. The funds will be used for the construction of new factories, market promotion, and the development of new products. Jexin Medical focuses on cardiovascular interventional fields such as cardiac electrophysiology and has established a complete product line covering interatrial puncture, mapping, ablation, and reanimation. Its interatrial puncture system and balloon mapping catheter have both obtained registration certificates from the National Medical Products Administration and are available on the market. The balloon mapping catheter has recently obtained national medical insurance classification and code for medical consumables.
Aikemai Medical DevicesBairen MedicalChengshu InvestmentHuitai MedicalJexin MedicalNewmai MedicalQianrong HoldingSanjiang Capital
Event frameEVENT FRAME
Funding / M&A数千万元
杰心医疗完成天使+轮融资，资金用于建厂及研发
Status
In September 2026, tens of millions of yuan in angel and Series A financing was completed. The funds were used for factory construction, market promotion, and research and development.
Coverage · reports per dayLANGUAGE SPLIT
Entity relations
Integrated timelineUNIFIED TIMELINE
2026-09-07
Jexin Medical received tens of millions of yuan in angel and Series A financing
Led by Chengshu Investment, with Sanjiang Capital and Qianrong Holding as follow-on investors, and existing shareholder Daoyuan Capital continuing to participate. The funds were used for new factory construction, market promotion, and new product development.
In September 2026, Shanghai Jexin Medical Technology Co., Ltd. completed angel + series A financing of tens of millions of yuan, led by Chengshu Investment, with participation from Sanjiang Capital and Qianrong Holding. The funds will be used to build new factories, promote market promotion, and accelerate the development of new products. Jexin Medical focuses on cardiovascular interventional fields such as cardiac electrophysiology. It has established a complete product line covering interatrial puncture, mapping, ablation, and rhythm restoration. Its interatrial puncture system and balloon mapping catheter have been approved for marketing, aiming to provide innovative surgical solutions for interventional doctors and patients.
Jexin Medical completed a Series A+ financing of tens of millions of yuan, with the funds used for factory construction, market promotion, and research and development. This round of financing was led by Chengshu Investment, with participation from Sanjiang Capital and Qianrong Holding, and continued support from existing shareholder Daoyuan Capital. Jexin Medical was established in 2024, with its headquarters located in Cixi City, Ningbo, Zhejiang Province, focusing on cardiovascular interventional markets such as cardiac electrophysiology. Its interatrial puncture system and balloon mapping catheter have obtained registration certificates from the National Medical Products Administration and are available on the market. The balloon mapping catheter has recently received classification and code approval for medical consumables under national medical insurance. Aikemai Medical Devices completed a Pre-B financing of over 100 million yuan; Newmai Medical’s IPO on the Sci-Tech Innovation Board was accepted, aiming to raise 1.364 billion yuan. Huaitai Medical’s intracardiac ultrasound catheters are currently advancing commercialization roadshows; Bairen Medical’s artificial heart valves saw a year-over-year increase of approximately 10.31% in sales, and the sales of interventional valves increased by more than 50%; Sainuo Medical’s coronary intervention business revenue increased by 21.92% year-on-year, and its nerve intervention business revenue increased by 5.30%.